A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort

A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort

Abstract Introduction Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as Palbociclib and Ribociclib, have significantly improved outcomes for patients with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer. Although clinical trials have established the efficacy of the...

Full description

Saved in:
Bibliographic Details
Main Authors: Nihanthy D. Sreenath, Suresh Pandalanghat, Amul Kapoor, Rajath Govind, M. R. Kaushik, Rajesh Nair, Dipen Bhuva, Anvesh Rathore, Manish Kumar, Deepak Mulajker
Format: Article
Language:English
Published: BMC 2025-08-01
Series:BMC Cancer
Subjects:
CDK4/6 inhibitors
HR+/HER2- breast cancer
Metastatic breast cancer
Palbociclib
Ribociclib
Real-world evidence
Online Access:https://doi.org/10.1186/s12885-025-14270-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-14270-1

Similar Items